vs
Esperion Therapeutics, Inc.（ESPR）与微策略（MSTR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是微策略的1.4倍（$168.4M vs $123.0M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 1.9%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.3%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Strategy Inc（原名为微策略）是1989年成立的美国上市企业，主营商业智能与移动软件业务，旗下产品可帮助企业分析内外部数据以支撑经营决策，还可用于移动应用开发，总部位于弗吉尼亚州泰森斯角，商业分析赛道核心竞品包括SAP等。
ESPR vs MSTR — 直观对比
营收规模更大
ESPR
是对方的1.4倍
$123.0M
营收增速更快
ESPR
高出141.8%
1.9%
两年增速更快
ESPR
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $123.0M |
| 净利润 | — | — |
| 毛利率 | — | 66.1% |
| 营业利润率 | 50.6% | — |
| 净利率 | — | — |
| 营收同比 | 143.7% | 1.9% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.32 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRMSTR
| Q4 25 | $168.4M | $123.0M | ||
| Q3 25 | $87.3M | $128.7M | ||
| Q2 25 | $82.4M | $114.5M | ||
| Q1 25 | $65.0M | $111.1M | ||
| Q4 24 | $69.1M | $120.7M | ||
| Q3 24 | $51.6M | $116.1M | ||
| Q2 24 | $73.8M | $111.4M | ||
| Q1 24 | $137.7M | $115.2M |
净利润ESPRMSTR
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $2.8B | ||
| Q2 25 | $-12.7M | $10.0B | ||
| Q1 25 | $-40.5M | $-4.2B | ||
| Q4 24 | — | $-670.8M | ||
| Q3 24 | $-29.5M | $-340.2M | ||
| Q2 24 | $-61.9M | $-102.6M | ||
| Q1 24 | $61.0M | $-53.1M |
毛利率ESPRMSTR
| Q4 25 | — | 66.1% | ||
| Q3 25 | — | 70.5% | ||
| Q2 25 | — | 68.8% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 71.7% | ||
| Q3 24 | — | 70.4% | ||
| Q2 24 | — | 72.2% | ||
| Q1 24 | — | 74.0% |
营业利润率ESPRMSTR
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | -5331.4% | ||
| Q4 24 | -6.4% | -842.1% | ||
| Q3 24 | -31.0% | -372.7% | ||
| Q2 24 | 3.5% | -179.7% | ||
| Q1 24 | 52.5% | -176.8% |
净利率ESPRMSTR
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 2164.1% | ||
| Q2 25 | -15.4% | 8752.7% | ||
| Q1 25 | -62.2% | -3797.2% | ||
| Q4 24 | — | -555.8% | ||
| Q3 24 | -57.2% | -293.1% | ||
| Q2 24 | -83.9% | -92.0% | ||
| Q1 24 | 44.3% | -46.1% |
每股收益（稀释后）ESPRMSTR
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $8.42 | ||
| Q2 25 | $-0.06 | $32.60 | ||
| Q1 25 | $-0.21 | $-16.49 | ||
| Q4 24 | $-0.14 | $4.49 | ||
| Q3 24 | $-0.15 | $-1.72 | ||
| Q2 24 | $-0.33 | $-0.57 | ||
| Q1 24 | $0.34 | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $2.3B |
| 总债务越低越好 | — | $8.2B |
| 股东权益账面价值 | $-302.0M | $44.1B |
| 总资产 | $465.9M | $61.6B |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资ESPRMSTR
| Q4 25 | $167.9M | $2.3B | ||
| Q3 25 | $92.4M | $54.3M | ||
| Q2 25 | $86.1M | $50.1M | ||
| Q1 25 | $114.6M | $60.3M | ||
| Q4 24 | $144.8M | $38.1M | ||
| Q3 24 | $144.7M | $46.3M | ||
| Q2 24 | $189.3M | $66.9M | ||
| Q1 24 | $226.6M | $81.3M |
总债务ESPRMSTR
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | $8.2B | ||
| Q2 25 | — | $8.2B | ||
| Q1 25 | — | $8.1B | ||
| Q4 24 | — | $7.2B | ||
| Q3 24 | — | $4.2B | ||
| Q2 24 | — | $3.8B | ||
| Q1 24 | — | $3.6B |
股东权益ESPRMSTR
| Q4 25 | $-302.0M | $44.1B | ||
| Q3 25 | $-451.4M | $52.3B | ||
| Q2 25 | $-433.5M | $47.5B | ||
| Q1 25 | $-426.2M | $32.2B | ||
| Q4 24 | $-388.7M | $18.2B | ||
| Q3 24 | $-370.2M | $3.8B | ||
| Q2 24 | $-344.2M | $2.8B | ||
| Q1 24 | $-294.3M | $2.4B |
总资产ESPRMSTR
| Q4 25 | $465.9M | $61.6B | ||
| Q3 25 | $364.0M | $73.6B | ||
| Q2 25 | $347.1M | $64.8B | ||
| Q1 25 | $324.0M | $43.9B | ||
| Q4 24 | $343.8M | $25.8B | ||
| Q3 24 | $314.1M | $8.3B | ||
| Q2 24 | $352.3M | $7.1B | ||
| Q1 24 | $373.1M | $6.4B |
负债/权益比ESPRMSTR
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRMSTR
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $-8.3M | ||
| Q2 25 | $-31.4M | $-34.9M | ||
| Q1 25 | $-22.6M | $-2.4M | ||
| Q4 24 | $-35.0M | $-17.3M | ||
| Q3 24 | $-35.3M | $-41.0M | ||
| Q2 24 | $-7.2M | $-23.3M | ||
| Q1 24 | $53.8M | $28.6M |
自由现金流ESPRMSTR
| Q4 25 | — | — | ||
| Q3 25 | — | $-11.1M | ||
| Q2 25 | — | $-37.0M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | — | $-17.6M | ||
| Q3 24 | $-35.5M | $-41.4M | ||
| Q2 24 | $-7.3M | $-24.1M | ||
| Q1 24 | $53.8M | $27.0M |
自由现金流率ESPRMSTR
| Q4 25 | — | — | ||
| Q3 25 | — | -8.6% | ||
| Q2 25 | — | -32.3% | ||
| Q1 25 | — | -4.6% | ||
| Q4 24 | — | -14.6% | ||
| Q3 24 | -68.7% | -35.7% | ||
| Q2 24 | -9.9% | -21.6% | ||
| Q1 24 | 39.0% | 23.5% |
资本支出强度ESPRMSTR
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 2.5% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.4% | ||
| Q2 24 | 0.1% | 0.6% | ||
| Q1 24 | 0.1% | 1.3% |
现金转化率ESPRMSTR
| Q4 25 | — | — | ||
| Q3 25 | — | -0.00× | ||
| Q2 25 | — | -0.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MSTR
暂无分部数据
